# Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

> **NCT00003962** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** aldesleukin

## Key facts

- **NCT ID:** NCT00003962
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-04
- **Primary completion:** 2000-06
- **Final completion:** 2000-06
- **Target enrollment:** — (—)
- **Last updated:** 2014-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003962, "Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00003962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*